The FDA is reviewing
BPC-157. We’re covering
every step.
A formal Pharmacy Compounding Advisory Committee hearing is set for July 23, 2026. Every other source on BPC-157 has something to sell. We don’t — just the regulatory record, translated into plain English.
BPC-157 is not FDA approved and compounding access is restricted.
A formal Pharmacy Compounding Advisory Committee (PCAC) discussion is scheduled for July 23, 2026 — part of the FDA’s 503A bulks list review process. A PCAC discussion is an advisory step, not an approval. Nothing on BPC157.now constitutes an offer to sell, prescribe, or dispense BPC-157.
FDA briefing documents for the July 23, 2026 PCAC meeting have not yet been released. When they are, we’ll summarize them in plain language within 24 hours. Subscribe to get notified.
We built this because every other source has something to sell.
The BPC-157 information problem is straightforward: vendors frame regulatory risk as a temporary inconvenience. Clinic websites describe legal gray areas as “access challenges.” Reddit threads cite each other until the original FDA document is three levels removed.
We have nothing to sell. Our job is to read the actual PCAC briefing materials, track every step of the formal 503A review process, and explain what each development does — and doesn’t — mean.
- We read primary FDA documents, not vendor summaries
- No affiliate deals, no product links, no sales — ever
- Plain-English summaries of PCAC briefings within 24 hours of release
- If compliant access options emerge, subscribers hear before anyone else
If you’ve been down this rabbit hole, you know the problem.
You’ve probably read the PubMed abstracts, scanned r/Peptides, and tried to parse FDA guidance documents that weren’t written for a general audience. You know BPC-157 has pre-clinical data. You also know that “animal studies” and “it works” are not the same sentence.
Two questions come up every time: What does the evidence actually say? And What’s the legal status right now? We answer both — carefully — and update when the answer changes.
Four categories. Zero sales language.
Every piece we publish fits into one of these tracks. Nothing else.
FDA process tracking
We follow the 503A bulks list nomination, PCAC advisory process, and formal rulemaking step by step — and explain what each one does and doesn't mean for BPC-157.
Regulatory news desk
Short, sourced summaries of BPC-157 developments as they happen. No aggregated clickbait, no press-release rewrites — original editorial work.
Research context
An honest map of the evidence: what kind of studies exist, where the gaps are, and what questions to actually raise with a licensed professional.
Future availability alerts
If compliant access options emerge from formal regulatory action, we surface them as educational notifications — not referrals, not advertisements.
Latest from the news desk
Sourced, editorial, independently written — not aggregated from press releases.
The formal FDA process, in order
BPC-157-related substances are moving through a structured, public regulatory process. Here is the timeline in plain language.
- 2021
FDA begins broader peptide enforcement and guidance clarification
The FDA issued guidance and enforcement actions targeting compounded peptide products that had proliferated outside the 503A framework. This set the stage for formal substance-by-substance review of the peptide compounding landscape, including BPC-157-related substances.
- 2023
FDA formally flags safety concerns around specific compounded peptides
The FDA publicly identified safety signals associated with certain compounded peptide products — citing gaps in identity, purity, and potency data, and limited human clinical evidence. BPC-157-related substances were among those in the broader category under evaluation.
- 2025
BPC-157-related substances nominated for 503A bulks list consideration
Nominations requesting formal FDA evaluation of BPC-157-related substances for possible inclusion on the 503A bulks list were advanced through the public nomination process. This triggered the formal review pathway that leads to a PCAC discussion.
- 2026
FDA schedules July 23 PCAC discussion for BPC-157-related substances
The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to publicly discuss BPC-157-related bulk drug substances on July 23, 2026, as part of the 503A nomination process. The committee will review available evidence and produce a recommendation — not a binding rule.
- Current status
Not FDA approved — and not offered through this website
BPC-157 is not FDA approved as a drug. Compounded access is restricted under current rules. BPC157.now does not sell, prescribe, dispense, or ship BPC-157 or related products. This site is informational only.
- Future
Any change requires formal rulemaking after advisory input
A PCAC recommendation — favorable or not — is one input into a longer process: FDA notice of proposed rulemaking, public comment period, then a final rule. Any material change to BPC-157's compounding status will follow that sequence. We will summarize each step as it happens.
Common questions, answered carefully
We try to keep answers short, accurate, and free of marketing language. If you do not see your question, reach out.
See full FAQ
The FDA briefing documents
aren’t public yet.
You’ll want our summary
when they drop.
We summarize FDA materials within 24 hours of release — what the documents actually say, stripped of marketing spin.
- We read the primary source documents, not third-party summaries
- Zero product recommendations, now or ever
- Regulatory updates before the rumors start spreading
Get the briefing summary when it drops.
FDA materials for the July 23 PCAC meeting aren't public yet. We'll summarize them within 24 hours of release — free.
BPC157.now does not sell, prescribe, or dispense BPC-157. Informational only.